หน้าแรก
ค้นหา
Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma
Dr. Kluger on the Toxicity Profile of Concurrent Nivolumab and Ipilimumab
Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab for Advanced Melanoma
Dr. Luke Discusses the Controversy Surrounding Ipilimumab/Nivolumab Combo in Melanoma
Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma
Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma
Dr. Kluger on Toxicities Associated With Immunotherapies
Dr. Kluger on How Immunotherapies are Changing the Treatment of Melanoma
The safety of nivolumab for advanced melanoma
Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma
Dr. Kluger on the Changing Landscape of Immunotherapies for the Treatment of Melanoma
Ipilimumab Combined With Nivolumab for Patients With Melanoma
Dr. Kluger on the Changes and Challenges of Treating Melanoma
Nivolumab Plus Ipilimumab in Advanced Melanoma
Dr. Kluger on Immunotherapy in Melanoma
Nivolumab and salvage nivolumab plus ipilimumab for aRCC
Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma
Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma
Dr. Kluger on the Difference Between Blocking PD-1 and PD-L1 in Melanoma
The Significance of the Ipilimumab/Nivolumab Findings in Melanoma
